Humana Inc. (NYSE:HUM) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts give Humana a consensus "Hold" rating from 26 brokers (4 sell, 15 hold, 7 buy) with an average 12‑month price target of $222.09.
• Several firms recently trimmed targets or downgraded the stock — Robert W. Baird cut its target to $205 (neutral), Raymond James trimmed to $230 (outperform), Deutsche Bank set $180 (hold), and Zacks downgraded to "strong sell".
• Humana beat the latest quarter (EPS -$3.96 vs. -$4.01; revenue $32.64B, +11.3% y/y), set FY2026 guidance of 9.00 EPS, and pays a quarterly dividend of $0.885 (annual $3.54, ~1.6% yield).

Humana Inc. (NYSE:HUM - Get Free Report) has been given a consensus recommendation of "Hold" by the twenty-six brokerages that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $222.0870.

Several analysts recently weighed in on HUM shares. Robert W. Baird decreased their target price on Humana from $264.00 to $205.00 and set a "neutral" rating for the company in a research note on Wednesday, April 15th. UBS Group reiterated a "neutral" rating on shares of Humana in a research report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft set a $180.00 price objective on Humana and gave the stock a "hold" rating in a research report on Friday, February 13th. Raymond James Financial reduced their price objective on Humana from $340.00 to $230.00 and set an "outperform" rating for the company in a research report on Friday, February 13th. Finally, Zacks Research downgraded Humana from a "hold" rating to a "strong sell" rating in a research report on Tuesday, April 14th.

Insider Activity

In related news, insider Sanjay K. Shetty bought 810 shares of the company's stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $185.21 per share, with a total value of $150,020.10. Following the acquisition, the insider owned 11,657 shares in the company, valued at approximately $2,158,992.97. This represents a 7.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company's stock.

Institutional Investors Weigh In On Humana

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sound View Wealth Advisors Group LLC increased its stake in shares of Humana by 3.5% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider's stock worth $272,000 after purchasing an additional 36 shares during the last quarter. Unison Advisors LLC increased its stake in shares of Humana by 0.4% during the 3rd quarter. Unison Advisors LLC now owns 10,137 shares of the insurance provider's stock worth $2,646,000 after purchasing an additional 37 shares during the last quarter. CoreCap Advisors LLC increased its stake in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider's stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Insigneo Advisory Services LLC increased its stake in shares of Humana by 3.0% during the 3rd quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider's stock worth $386,000 after purchasing an additional 43 shares during the last quarter. Finally, Columbus Macro LLC increased its stake in shares of Humana by 5.5% during the 4th quarter. Columbus Macro LLC now owns 821 shares of the insurance provider's stock worth $210,000 after purchasing an additional 43 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Shares of NYSE:HUM opened at $215.26 on Friday. The business has a 50 day moving average price of $184.64 and a 200 day moving average price of $229.11. Humana has a twelve month low of $163.11 and a twelve month high of $315.35. The company has a market cap of $25.84 billion, a price-to-earnings ratio of 21.92, a PEG ratio of 2.30 and a beta of 0.44. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. During the same quarter in the prior year, the company earned ($2.16) EPS. The firm's revenue for the quarter was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Research analysts predict that Humana will post 9.05 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.6%. Humana's dividend payout ratio (DPR) is currently 36.05%.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.